Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that ...

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a global scale. We also syndicate our video library in ...

The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic oesophagitis (EoE) in young patients. The drug has been specifically authorised for ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

GCI Health has announced the appointment of Annalise Coady as president, UK market lead and EMEA head of growth. Coady brings over two decades of experience in building and scaling marketing ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from Chimagen Biosciences in a deal worth $850m. GSK said it plans to develop and ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated inflammatory disease that ...

UCB has announced “encouraging data” from a phase 2a study of its investigational anti-tau antibody bepranemab in Alzheimer’s disease (AD) patients. The TOGETHER study has been evaluating the safety, ...

Principal Medical Writer, Dr Alexandra Loveday explores the importance of storytelling in health communications. Medical facts alone don’t change minds—stories do. Originating from the broader ...